Lung Adenocarcinoma
Conditions
Brief summary
Cancer immunotherapy has the great potential to achieve long-term survival in patients with a solid malignancy. However, the beneficial effect of cancer immunotherapy is seen in only a minority of patients. Mounting evidence suggests that immunosuppressive features in the tumor microenvironment prevent an effective antitumor defense. The aim of the investigators is to comprehensively analyze the cytokine profile and the tumor immune infiltrate in the tumor microenvironment and to investigate its prognostic significance in patients with radically resected lung adenocarcinoma.
Interventions
None listed
Sponsors
University Hospital Heidelberg
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Lung adenocarcinoma * Tumor stage IB and II * With or without adjuvant therapy * Complete surgical resection (R0) * No distant metastasis at the time of surgery (M0)
Exclusion criteria
• Second cancer within 5 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of surgery until the date of death from any cause assessed up to 100 months | Association of tumor microenvironment with overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Association of tumor microenvironment with recurrence-free survival |
Outcome results
None listed